A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma-Reference-Cited by-同舟云学术

A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma

Published:2019-10-20 Issue: Volume:2019 Page:1-4
ISSN:2090-6560
Container-title:Case Reports in Hematology
language:en
Short-container-title:Case Reports in Hematology

Author:

Katz Heather¹^ORCID,Shenouda Mina²,Dahshan Deena³,Sonnier George⁴,Lebowicz Yehuda⁵

Affiliation:

1. Department of Hematology/Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, Hempstead, NY 11549, USA

2. Department of Hematology/Oncology, Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr., Huntington, WV 25701, USA

3. Joan C. Edwards School of Medicine, Marshall University, 1600 Medical Center Dr., Huntington, WV 25701, USA

4. Department of Dermatology, University of Louisville School of Medicine, Louisville, KY 40203, USA

5. Department of Hematology/Oncology, UPMC Hillman Cancer Center, 1030 Beaver Hollow Rd., Beaver, PA 15009, USA

Abstract

Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who was started on ixazomib, lenalidomide, and dexamethasone. He developed several skin lesions that were biopsied and revealed cutaneous necrotizing vasculitis. Ixazomib was held with resolution of the vasculitic lesions and restarted with dexamethasone to 20 mg on the day of treatment and 20 mg dose the day after treatment.

Publisher

Hindawi Limited

Subject

Cell Biology,Developmental Biology,Embryology,Anatomy

Link

http://downloads.hindawi.com/journals/crihem/2019/6061484.pdf

Reference12 articles.

1. Treatment of relapsed and refractory multiple myeloma

2. Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

3. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

4. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

5. Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib/ixazomib/lenalidomide;Reactions Weekly;2023-03-04

2. Sweet Syndrome Associated with Ixazomib;Turkish Journal of Hematology;2021-06-11